https://qz.com/pfizer-fda-novo-nordisk-ftc-1851588254
Pfizer said on Thursday that it is advancing development of a once-daily weight loss pill, which it believes could be competitive in the GLP-1 space. The U.S. Food and Drug Administration (FDA) did not approve Novo Nordisk’s once-weekly insulin. And the U.S. Federal Trade Commission (FTC) said in a report that…Read more…
Pfizer’s weight loss pill, FDA rejects Novo’s weekly insulin, and FTC says drug middlemen are hiking prices: Pharma news round up
Published in Business and Uncategorized
More from BusinessMore posts in Business »
- Wise Group shares tank after U.S. bank charter rejected. What’s next for the fintech.
- Structural timber promoted at Westminster
- Thinking local brings EcoVadis Gold for MKM
- Work starts on Wolverhampton new homes
- Battle starts for places in £8bn national roads upkeep shake-up
- Woodalls appoints in France and Spain
- NEET-UG paper leak row: SC directs Centre, NTA to file detailed affidavits on progress made in implementing reforms
- Tier ones called up for £500m building safety framework
- Henry Brothers opens new Edinburgh office
- Who is Naresh Pal Gangwar? IAS officer appointed as education secretary amid nationwide student protests
More from UncategorizedMore posts in Uncategorized »
- The Resonance of High Dividends and Prudent Capital Management: Defensive Value Revaluation of CMBC Capital (1141.HK)
- Wise Group shares tank after U.S. bank charter rejected. What’s next for the fintech.
- Structural timber promoted at Westminster
- Thinking local brings EcoVadis Gold for MKM
- Work starts on Wolverhampton new homes
- Battle starts for places in £8bn national roads upkeep shake-up
- Woodalls appoints in France and Spain
- NEET-UG paper leak row: SC directs Centre, NTA to file detailed affidavits on progress made in implementing reforms
- Tier ones called up for £500m building safety framework
- Henry Brothers opens new Edinburgh office
